Д. А. Шапиро

10.7k total citations · 4 hit papers
178 papers, 7.3k citations indexed

About

Д. А. Шапиро is a scholar working on Atomic and Molecular Physics, and Optics, Electrical and Electronic Engineering and Hepatology. According to data from OpenAlex, Д. А. Шапиро has authored 178 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Atomic and Molecular Physics, and Optics, 53 papers in Electrical and Electronic Engineering and 34 papers in Hepatology. Recurrent topics in Д. А. Шапиро's work include Liver Diseases and Immunity (27 papers), Liver Disease Diagnosis and Treatment (27 papers) and Advanced Fiber Laser Technologies (19 papers). Д. А. Шапиро is often cited by papers focused on Liver Diseases and Immunity (27 papers), Liver Disease Diagnosis and Treatment (27 papers) and Advanced Fiber Laser Technologies (19 papers). Д. А. Шапиро collaborates with scholars based in Russia, United States and United Kingdom. Д. А. Шапиро's co-authors include Bryan L. Roth, Luciano Adorini, Mark Pruzanski, William B. Stiles, Hanns–Ulrich Marschall, Louis A. Chiodo, Richard B. Mailman, David R. Sibley, Erin Castelloe and Michael Barkham and has published in prestigious journals such as New England Journal of Medicine, Physical Review Letters and Journal of Biological Chemistry.

In The Last Decade

Д. А. Шапиро

158 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2010 1.1k citations Д. А. Шапиро et al. profile →
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

2003 771 citations Д. А. Шапиро, Louis A. Chiodo et al. Neuropsychopharmacology profile →
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

2013 767 citations Sunder Mudaliar, Robert R. Henry et al. Gastroenterology profile →
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

2014 421 citations Gideon M. Hirschfield, Andrew L. Mason et al. Gastroenterology profile →

Peers

Countries citing papers authored by Д. А. Шапиро

Since Specialization

Citations

This map shows the geographic impact of Д. А. Шапиро's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Д. А. Шапиро with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Д. А. Шапиро more than expected).

Fields of papers citing papers by Д. А. Шапиро

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Д. А. Шапиро. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Д. А. Шапиро. The network helps show where Д. А. Шапиро may publish in the future.

Co-authorship network of co-authors of Д. А. Шапиро

This figure shows the co-authorship network connecting the top 25 collaborators of Д. А. Шапиро. A scholar is included among the top collaborators of Д. А. Шапиро based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Д. А. Шапиро. Д. А. Шапиро is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual-phase modulation via Mo doping and Li₃PO₄ coating for stabilized LiNi_0.9Mn_0.07Co_0.02Al_0.01O₂ cathodes in high-energy lithium-ion batteries 2025 ·Journal of Materials Chemistry A ·Srinivasan Alagar, Jun Soo Kim, Eun-Jung Shin, Alexander S. Ditter, Д. А. Шапиро, Namdong Kim, Won G. Hong, (unknown), Young‐Sang Yu, Gi Dae Park, Sang Mun Jeong	1
2	Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling 2025 ·Alimentary Pharmacology & Therapeutics ·Amrik Shah, Leigh MacConell, A. Sender Liberman, Adrian M. Di Bisceglie, Д. А. Шапиро	1
3	Modeling of Subwavelength Gratings: Near-Field Behavior 2023 ·Photonics ·(unknown), (unknown), Л. Л. Фрумин, Д. А. Шапиро	0
4	Light Scattering by a Subwavelength Plasmonic Array: Anisotropic Model 2022 ·Sensors ·(unknown), Л. Л. Фрумин, Д. А. Шапиро	1
5	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis 2020 ·Journal of Hepatology ·Kris V. Kowdley, Raj Vuppalanchi, Cynthia Levy, Annarosa Floreani, Pietro Andreoné, Nicholas F. LaRusso, Roshan Shrestha, James F. Trotter, David Goldberg, Simon Rushbrook, Gideon M. Hirschfield, Thomas D. Schiano, Yuying Jin, Richard Pencek, Leigh MacConell, Д. А. Шапиро, Christopher L. Bowlus	142
6	FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid 2018 ·Gastroenterology ·Elliot S. Friedman, Yun Li, Ting‐Chin David Shen, Jack Jiang, Lillian Chau, Luciano Adorini, Farah Babakhani, Jeffrey E. Edwards, Д. А. Шапиро, Chunyu Zhao, Rotonya M. Carr, Kyle Bittinger, Hongzhe Li, Gary D. Wu	120
7	Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH 2018 ·PubMed Central ·Naga Chalasani, Manal F. Abdelmalek, Rohit Loomba, Kris V. Kowdley, Arthur J. McCullough, Srinivasan Dasarathy, Brent A. Neuschwander‐Tetri, Norah A. Terrault, (unknown), Reshma Shringarpure, Д. А. Шапиро, Arun J. Sanyal	6
8	PTU-193 A Novel, Rational Approach to Treating Primary Bile Acid Diarrhoea: a Proof of Concept Study of the FXR Agonist Obeticholic Acid 2013 ·Gut ·Iain G. Johnston, (unknown), Tracy Dew, Д. А. Шапиро, Julian R.F. Walters	3
9	Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease breakdown → 2013 ·Gastroenterology ·Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal, Linda Morrow, Hanns–Ulrich Marschall, Mark Kipnes, Luciano Adorini, (unknown), Paul Clopton, Erin Castelloe, Paul Dillon, Mark Pruzanski, Д. А. Шапиро	767
10	28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC 2011 ·Journal of Hepatology ·Kris V. Kowdley, (unknown), Velimir A. Luketic, Robert Chapman, A.K. Burroughs, Gideon M. Hirschfield, Raoul Poupon, Christoph Schramm, (unknown), C Rust, Albert Parés, Andrew L. Mason, (unknown), (unknown), O. Böhm, Erin Castelloe, Mark Pruzanski, Д. А. Шапиро	47
11	OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC: Abstract OP02 Table 1 2011 ·Gut ·Diana Jones, Kris V. Kowdley, Robert Chapman, Andrew K. Burroughs, Gideon M. Hirschfield, Christoph Schramm, Raoul Poupon, Albert Parés, Д. А. Шапиро, Mark Pruzanski, (unknown)	13
12	A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY 2009 ·Hepatology ·(unknown), Sunder Mudaliar, (unknown), (unknown), Linda Morrow, (unknown), Paul Dillon, Paul Clopton, Mark Kipnes, Д. А. Шапиро	18
13	P3-138: A Phase I open label study of continuous oral treatment with BIBF 1120 together with carboplatin and paclitaxel treated patients with non–small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·D. Ross Camidge, Paul Conkling, Joe Stephenson, Д. А. Шапиро	9
14	P3-091: A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer 2007 ·Journal of Thoracic Oncology ·Nasser H. Hanna, Peter Ellis, Peter Stopfer, Д. А. Шапиро, Steve Gyorffy	10
15	Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury 2006 ·American Journal of Transplantation ·(unknown), Kenneth Washburn, Sandy Feng, Tilman Oltersdorf, Д. А. Шапиро, (unknown), Lawrence J. Burgart, Megan Garrity-Park, (unknown), (unknown), (unknown), (unknown)	146
16	Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology breakdown → 2003 ·Neuropsychopharmacology ·Д. А. Шапиро, (unknown), (unknown), Louis A. Chiodo, (unknown), David R. Sibley, Bryan L. Roth, Richard B. Mailman	771
17	γ3 Gene-Disrupted Mice Selectively Deficient in the Dominant IgG Subclass Made to Bacterial Polysaccharides. II. Increased Susceptibility to Fatal Pneumococcal Sepsis Due to Absence of Anti-Polysaccharide IgG3 Is Corrected by Induction of Anti-Polysaccharide IgG1 2002 ·The Journal of Immunology ·(unknown), Ethan G. Leonard, (unknown), Д. А. Шапиро, Neil S. Greenspan, John R. Schreiber	48
18	Evidence for a Model of Agonist-induced Activation of 5-Hydroxytryptamine 2A Serotonin Receptors That Involves the Disruption of a Strong Ionic Interaction between Helices 3 and 6 2002 ·Journal of Biological Chemistry ·Д. А. Шапиро, Kurt Kristiansen, David M. Weiner, Wesley K. Kroeze, Bryan L. Roth	142
19	Low-pressure arc in a transverse gas flow 1985 ·Soviet physics. Technical physics ·Д. А. Шапиро	1
20	Spectral line broadening due to Coulomb interaction 1979 ·Journal of Experimental and Theoretical Physics ·(unknown), Д. А. Шапиро	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact